Free Webinar
Register today—space is limited.

AUA Prostate Cancer Webinar:
Understanding and Defining Risk
Eric A. Klein, M.D.
Professor of Urology
Cleveland Clinic Foundation
Cleveland, OH

September 10, 2008, 8:00 p.m. EDT

Description/Purpose/Need
The American Urological Association (AUA) is proud to offer a FREE Prostate Cancer Webinar Series on many topics related to the treatment of prostate cancer, presented by expert faculty from around the country. The AUA is proud to offer a the first of a series of FREE Prostate Cancer Webinars on many topics related to the treatment of prostate cancer, presented by expert faculty from around the country. This is an opportunity to gain 0.5 AMA PRA Category 1 Credits™ for each webinar you view without leaving your home or office.

The three known risk factors for prostate cancer (age, race, and family history) have limited ability to predict the risk of disease for an individual patient. Data from the PCPT and other studies have identified new variables that impact on risk and led to the development of sophisticated yet simple to use risk calculators that expand upon these factors along with PSA that can be easily incorporated into daily practice. Evolution in genetic testing has now identified certain chromosomal variants that also accurately identify individuals at increased risk and will be commercially available in the near future. This presentation will synthesize these developments into a usable context.

Attendance is limited for the live program. 30-minute program with a 15-minute question-and-answer period following the presentation. Program will also be available on-line the day after the live event.

Supported by an educational grant from GlaxoSmithKline.

Target Audience
This program is designed for all who treat prostate cancer, primarily urologists and radiation oncologists, with additional interest during September for internists, family practice and allied health professionals.

Learning Objectives
After completing this module, the participant will be able to:

1. List known risk factors for prostate cancer
2. Evaluate the utility and limitations of PSA as a risk marker for prostate cancer
3. Develop a rationale for using sophisticated prediction models in routine clinical practice
4. Discuss new genetic models and their potential clinical use

Accreditation
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AUA takes responsibility for the content, quality, and scientific integrity of this CME activity.

Credit Designation
The American Urological Association designates this educational series for a maximum of 5.5 AMA PRA Category 1 Credits™ or each webinar activity for 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

AUA Disclosure Policy
As a provider accredited by the ACCME, the AUA must insure balance, independence, objectivity and scientific rigor in all its activities.

All faculty participating in an educational activity provided by the AUA are required to disclose to the audience any relevant financial relationships with any commercial interest to the provider. The intent of this disclosure is not to prevent faculty with relevant financial relationships from serving as faculty, but rather to provide members of the audience with information on which they can make their own judgments. The AUA must resolve any conflicts of interest prior to the commencement of the educational activity. It remains for the audience to determine if the faculty's relationships may influence the educational content with regard to exposition or conclusion. When unlabeled or unapproved uses are discussed, these are also indicated.

Unlabeled or Unapproved Use of Drugs or Devices
It is the policy of the AUA to require the disclosure of all references to unlabeled or unapproved uses or drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to unlabeled or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer
The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Evidence-based Content
As a provider of continuing medical education accredited by the ACCME, it is the policy of the AUA to review and certify that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.